Literature DB >> 12591732

Loss of heterozygosity of chromosome 1q in gastrinomas: occurrence and prognostic significance.

Yuan-Jia Chen1, Alexander Vortmeyer, Zhengping Zhuang, Steve Huang, Robert T Jensen.   

Abstract

A proportion of gastrinomas demonstrates aggressive growth, and most deaths occur in this group. Little is known about the molecular pathogenesis of growth of this tumor, and there are no predictive factors that are useful in an individual patient. Chromosome 1 (Chr 1) loss of heterozygosity (LOH) is frequent in a number of nonendocrine tumors and in a few endocrine tumors, and its presence can correlate with tumor aggressiveness and survival. In gastrointestinal endocrine tumors including gastrinomas, little data are available on Chr 1 LOH, and the limited results are contradictory. In the present study we determine whether Chr 1 LOH occurs in gastrinomas and is associated with aggressive growth by performing Chr 1 allelotyping with microsatellite markers in microdissected tumor tissue from 27 human gastrinomas and the leukocyte DNA of the patients. Detailed clinical pathological correlations were possible, because tumor growth in all of the patients was prospectively assessed with yearly imaging studies. Twelve gastrinomas (44%) had Chr 1 LOH, and in all of the cases 1q LOH occurred. 1q LOH was associated with aggressive growth (P = 0.0004), presence of liver metastases (P = 0.019), and postoperative development of hepatic metastases (P = 0.017). Eight (75%) of the 12 tumors with 1q LOH had 1q31-32 LOH over a 17.3 cM region, whereas LOH in 6 tumors (50%) occurred at 1q21-23 over a 12.3 cM area. The presence of 1q31-32 LOH and 1q21-23 LOH correlated with aggressive tumor growth (P = 0.0056 and P = 0.0031, respectively), and with postoperative development of liver metastases (P = 0.0114 and P = 0.011, respectively). These data suggest that 1q LOH is not infrequent in gastrinomas and could be a molecular/genetic prognostic factor for aggressive growth that could be useful clinically. The high frequent allelic loss at 1q31-32 as well as 1q21-23, which was associated with tumor aggressive growth, suggests these two regions harbor putative tumor suppressor gene(s) that are important for aggressive growth of this tumor.

Entities:  

Mesh:

Year:  2003        PMID: 12591732

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

Review 1.  Genetics of pancreatic neuroendocrine tumors: implications for the clinic.

Authors:  Antonio Pea; Ralph H Hruban; Laura D Wood
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-09-28       Impact factor: 3.869

Review 2.  Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.

Authors:  Robert T Jensen; Marc J Berna; David B Bingham; Jeffrey A Norton
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

3.  Downregulation of CRNN gene and genomic instability at 1q21.3 in oral squamous cell carcinoma.

Authors:  Iman Salahshourifar; Vui King Vincent-Chong; Hong-Yun Chang; Hooi Leng Ser; Anand Ramanathan; Thomas George Kallarakkal; Zainal Ariff Abdul Rahman; Siti Mazlipah Ismail; Narayanan Prepageran; Wan Mahadzir Wan Mustafa; Mannil Thomas Abraham; Keng Kiong Tay; Rosnah Binti Zain
Journal:  Clin Oral Investig       Date:  2015-04-08       Impact factor: 3.573

4.  PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors.

Authors:  Rieko Ohki; Kozue Saito; Yu Chen; Tatsuya Kawase; Nobuyoshi Hiraoka; Raira Saigawa; Maiko Minegishi; Yukie Aita; Goichi Yanai; Hiroko Shimizu; Shinichi Yachida; Naoaki Sakata; Ryuichiro Doi; Tomoo Kosuge; Kazuaki Shimada; Benjamin Tycko; Toshihiko Tsukada; Yae Kanai; Shoichiro Sumi; Hideo Namiki; Yoichi Taya; Tatsuhiro Shibata; Hitoshi Nakagama
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-27       Impact factor: 11.205

Review 5.  Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome.

Authors:  Fathia Gibril; Robert T Jensen
Journal:  Curr Gastroenterol Rep       Date:  2005-05

6.  Allelic deletion of the MEN1 gene in duodenal gastrin and somatostatin cell neoplasms and their precursor lesions.

Authors:  M Anlauf; A Perren; T Henopp; T Rudolf; N Garbrecht; A Schmitt; A Raffel; O Gimm; E Weihe; W T Knoefel; H Dralle; Ph U Heitz; P Komminoth; G Klöppel
Journal:  Gut       Date:  2006-11-29       Impact factor: 23.059

Review 7.  Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome.

Authors:  Jeffrey A Norton; Robert T Jensen
Journal:  Ann Surg       Date:  2004-11       Impact factor: 12.969

Review 8.  Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors.

Authors:  Thorvardur R Halfdanarson; Joseph Rubin; Michael B Farnell; Clive S Grant; Gloria M Petersen
Journal:  Endocr Relat Cancer       Date:  2008-06       Impact factor: 5.678

9.  Differential expression of S100 gene family in human esophageal squamous cell carcinoma.

Authors:  Junfang Ji; Liqun Zhao; Xiuqin Wang; Chuannong Zhou; Fang Ding; Lei Su; Chunlin Zhang; Xuezheng Mao; Min Wu; Zhihua Liu
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-04       Impact factor: 4.553

10.  Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas.

Authors:  Xin-Wei Qiao; Ling Qiu; Yuan-Jia Chen; Chang-Ting Meng; Zhao Sun; Chun-Mei Bai; Da-Chun Zhao; Tai-Ping Zhang; Yu-Pei Zhao; Yu-Li Song; Yu-Hong Wang; Jie Chen; Chong-Mei Lu
Journal:  BMC Endocr Disord       Date:  2014-08-07       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.